Skip to main content

NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Project description

Next-generation topical medication for the treatment of eczema

Field of science

  • /medical and health sciences/clinical medicine/dermatology

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

TIRMED PHARMA AB
Address
Spets Alviksvagen 1
16753 Bromma
Sweden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000